Rani Therapeutics Achieves Successful Oral Delivery of SEMAGLUTIDE via RANIPILL® HC

Summary

On February 5, Rani Therapeutics Holdings Inc. announced the successful preclinical data for oral delivery of semaglutide using RANIPILL® HC. RT-116 was well tolerated with no serious adverse events, and exhibited comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous administration. The first phase study of RT-114 is expected to launch in 2025.Benzinga

Impact Analysis

This event is categorized at the Company Level, specifically affecting Rani Therapeutics Holdings Inc. The successful demonstration of oral semaglutide delivery could position Rani Therapeutics as an innovator in drug delivery technology, potentially increasing its market share and attracting partnerships or acquisition interest from larger pharmaceutical companies. The comparable efficacy of oral administration to the traditional subcutaneous method could disrupt the diabetes treatment market, benefiting patients by providing a less invasive treatment option.Benzinga Immediate market reactions may include a positive impact on Rani Therapeutics’ stock price as investors react to the potential for increased revenue from new product offerings. Second-order effects could involve shifts in market dynamics as competitors may need to innovate or acquire similar technologies to remain competitive. Investment opportunities may arise in Rani Therapeutics’ stock, as well as in healthcare ETFs that include innovative pharmaceutical companies.Benzinga